Alex Wyatt: Will ctDNA serve as a treatment response biomarker in metastatic cancers
Alex Wyatt, Associate Professor at Vancouver Prostate Centre, shared a post on X about a recent paper published in Clinical Cancer Research.
Authors: Alexander Wyatt, Saskia Litière, Francois-Clement Bidard, Scott Laurie, Elena Garralda et al.
“Will ctDNA serve as a treatment response biomarker in metastatic cancers?
Here’s a thorough evaluation in Clinical Cancer Research from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond.”
Daniel Stover, Vice Chair of Alliance for Clinical Trials in Oncology, shared this post, adding:
“Imaging has limitations. ctDNA has limitations. Can the two together overcome the distinct limitations?
Very excited about some upcoming data from several studies Daniel Stover is doing with Foundation Medicine and, separately Broad Institute!”
Source: Alex Wyatt/X and Daniel Stover/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023